^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABBV-101

    i
    Other names: ABBV-101, ABBV 101, ABBV101
    Company:
    AbbVie
    Drug class:
    BTK degrader
    Related drugs:
    2ms
    A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (clinicaltrials.gov)
    P1, N=17, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion
    |
    ABBV-101
    4ms
    A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ABBV-101
    8ms
    A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (clinicaltrials.gov)
    P1, N=16, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABBV-101
    9ms
    A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, AbbVie
    New P1 trial
    |
    ABBV-101
    10ms
    Bruton Tyrosine Kinase Degraders: Current Concepts. (PubMed, Am J Clin Oncol)
    While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance-both intrinsic and acquired-poses a significant challenge, often associated with BTK mutations like C481S...Agents such as NRX-0492, BGB-16673, NX-5948, NX-2127, HZ-Q1060, ABBV-101, and AC676 have shown significant BTK degradation in preclinical and early clinical trials...These BTK degraders have demonstrated favorable safety profiles, with manageable adverse events, and offer a novel therapeutic avenue for patients with BTKi-resistant malignancies. As clinical trials progress, these degraders hold the potential to significantly enhance treatment outcomes, offering a new frontier in personalized cancer therapy.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    BTK C481S
    |
    Imbruvica (ibrutinib) • zelebrudomide (NX-2127) • ABBV-101 • NRX0492 • bexobrutideg (NX-5948) • catadegbrutinib (BGB-16673)
    10ms
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=244, Recruiting, AbbVie | N=128 --> 244 | Trial completion date: Apr 2029 --> Mar 2031 | Trial primary completion date: Jun 2027 --> Mar 2031
    Enrollment change • Trial completion date • Trial primary completion date • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    over1year
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Recruiting, AbbVie | Trial completion date: Jun 2027 --> Apr 2029
    Trial completion date • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ABBV-101
    almost2years
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Recruiting, AbbVie | N=188 --> 128
    Enrollment change • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    2years
    Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies (ASH 2023)
    ABBV-101 is currently in phase 1 clinical trial for a variety of B-cell malignancies. ClinicalTrials.gov identifier: NCT05753501
    Clinical • IO biomarker
    |
    BTK (Bruton Tyrosine Kinase)
    |
    BTK C481S • BTK mutation
    |
    ABBV-101
    over2years
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=188, Recruiting, AbbVie | N=128 --> 188
    Enrollment change • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    over2years
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    almost3years
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Not yet recruiting, AbbVie
    New P1 trial • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101